SCHEMBL3977060

SCHEMBL3977060

Cc1ccc(Oc2ncnc3ccccc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.57
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
RECQL P46063 1/20 0.55
RAB9A P51151 4/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
NPC1 O15118 3/20 0.51
TSHR P16473 1/20 0.51
KDR P35968 4/20 0.51
HTT P42858 4/20 0.50
LMNA P02545 2/20 0.50
RAF1 P04049 1/20 0.49
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3106181 0.87 EGFR (0.57) EGFRALDH1A1MAPTL3MBTL1RAB9A
SCHEMBL3979754 0.86 EGFR (0.69) EGFRALDH1A1MAPTL3MBTL1RAB9A
SCHEMBL8200916 0.83 EGFR (0.57) EGFRL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL17508505 0.83 EGFR (0.54) EGFRALDH1A1MAPTL3MBTL1RAB9A
Hydrochloric Acid SCHEMBL4731344 0.82 EGFR (0.56) EGFRL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL3635988 0.82 EGFR (0.62) EGFRL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL11286630 0.81 RAB9A (0.56) EGFRL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL4099491 0.80 RAB9A (0.60) EGFRALDH1A1MAPTRAB9ACYP1A2
SCHEMBL4078517 0.80 KDR (0.61) EGFRL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL3980790 0.80 EGFR (0.54) EGFRMAPTL3MBTL1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AHR, MALT1, ABL1 EGFR 456/4885ALDH1A1 1591/4885MAPT 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.